-
1
-
-
18844365126
-
Multiple sclerosis: Diagnosis and the management of acute relapses
-
Leary SM, Porter B, Thompson AJ. Multiple sclerosis: Diagnosis and the management of acute relapses. Postgrad Med J. 2005 ; 81: 302-308
-
(2005)
Postgrad Med J
, vol.81
, pp. 302-308
-
-
Leary, S.M.1
Porter, B.2
Thompson, A.J.3
-
2
-
-
0034101317
-
Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: Effects of heterogeneity of disease course in placebo cohorts
-
Liu C, Blumhardt LD. Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: Effects of heterogeneity of disease course in placebo cohorts. J Neurol Neurosurg Psychiatry. 2000 ; 68: 450-457
-
(2000)
J Neurol Neurosurg Psychiatry
, vol.68
, pp. 450-457
-
-
Liu, C.1
Blumhardt, L.D.2
-
3
-
-
52449117054
-
Disability as an outcome in MS clinical trials
-
Ebers GC, Heigenhauser L, Daumer M, et al. Disability as an outcome in MS clinical trials. Neurology. 2008 ; 71: 624-631
-
(2008)
Neurology
, vol.71
, pp. 624-631
-
-
Ebers, G.C.1
Heigenhauser, L.2
Daumer, M.3
-
4
-
-
0029082566
-
Copolymer i reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicentre, double-blind placebo-controlled trial
-
Johnson KP, Brooks BR, Cohen JA, et al. Copolymer I reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicentre, double-blind placebo-controlled trial. Neurology. 1995 ; 45: 1268-1276
-
(1995)
Neurology
, vol.45
, pp. 1268-1276
-
-
Johnson, K.P.1
Brooks, B.R.2
Cohen, J.A.3
-
5
-
-
84877008183
-
-
An extension protocol for multiple sclerosis patients who participated in Genzyme-sponsored studies of alemtuzumab. Sponsor: Genzyme; Collaborator: Bayer. ClinicalTrials.gov Identifier: NCT00930553 2010, accessed 8 November 2010
-
An extension protocol for multiple sclerosis patients who participated in Genzyme-sponsored studies of alemtuzumab. Sponsor: Genzyme; Collaborator: Bayer. ClinicalTrials.gov Identifier: NCT00930553http://clinicaltrials.gov/ct2/ show/NCT00930553?term=Multiple+Sclerosis,+edss+reduction&outc=EDSS&rank= 8 (2010, accessed 8 November 2010).
-
-
-
-
6
-
-
79952740129
-
Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: Post-hoc andsubset analyses of clinical efficacy outcomes
-
Coles AJ, Fox E, Vladic A, et al. Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: Post-hoc andsubset analyses of clinical efficacy outcomes. Lancet Neurol. 2011 ; 10: 338-348
-
(2011)
Lancet Neurol
, vol.10
, pp. 338-348
-
-
Coles, A.J.1
Fox, E.2
Vladic, A.3
-
7
-
-
0021035886
-
Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS)
-
Kurtzke J. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology. 1983 ; 33: 1444-1452
-
(1983)
Neurology
, vol.33
, pp. 1444-1452
-
-
Kurtzke, J.1
-
8
-
-
72449125358
-
Multiple sclerosis risk sharing scheme: Two year results of clinical cohort study with historical comparator
-
Boggild M, Palace J, Barton P, et al. Multiple sclerosis risk sharing scheme: Two year results of clinical cohort study with historical comparator. BMJ. 2009 ; 339: b4677
-
(2009)
BMJ
, vol.339
, pp. 4677
-
-
Boggild, M.1
Palace, J.2
Barton, P.3
-
9
-
-
0022629588
-
Prevalence of multiple sclerosis in British Columbia, Canada
-
Sweeney VP, Sadovnick AD, Brandejs V. Prevalence of multiple sclerosis in British Columbia, Canada. Can J Neurol Sci. 1986 ; 13: 47-51
-
(1986)
Can J Neurol Sci
, vol.13
, pp. 47-51
-
-
Sweeney, V.P.1
Sadovnick, A.D.2
Brandejs, V.3
-
10
-
-
0026780512
-
Life expectancy in patients attending multiple sclerosis clinics
-
Sadovnick AD, Ebers GC, Wilson RW, et al. Life expectancy in patients attending multiple sclerosis clinics. Neurology. 1992 ; 42: 991-994
-
(1992)
Neurology
, vol.42
, pp. 991-994
-
-
Sadovnick, A.D.1
Ebers, G.C.2
Wilson, R.W.3
-
11
-
-
33644887189
-
Disability progression in multiple sclerosis is slower than previously reported
-
Tremlett H, Paty D, Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology. 2006 ; 66: 172-177
-
(2006)
Neurology
, vol.66
, pp. 172-177
-
-
Tremlett, H.1
Paty, D.2
Devonshire, V.3
-
12
-
-
77953750773
-
New perspectives in the natural history of multiple sclerosis
-
Tremlett H, Zhao Y, Rieckmann P, et al. New perspectives in the natural history of multiple sclerosis. Neurology. 2010 ; 74: 2004-2015
-
(2010)
Neurology
, vol.74
, pp. 2004-2015
-
-
Tremlett, H.1
Zhao, Y.2
Rieckmann, P.3
-
13
-
-
0020686503
-
New diagnostic criteria for multiple sclerosis: Guidelines for research proposals
-
Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: Guidelines for research proposals. Ann Neurol. 1983 ; 13: 227-231
-
(1983)
Ann Neurol
, vol.13
, pp. 227-231
-
-
Poser, C.M.1
Paty, D.W.2
Scheinberg, L.3
-
15
-
-
0024205301
-
Models for longitudinal data: A generalized estimating equation approach
-
Zeger SL, Liang KY, Albert PS. Models for longitudinal data: A generalized estimating equation approach. Biometrics. 1988 ; 44: 1049-1060
-
(1988)
Biometrics
, vol.44
, pp. 1049-1060
-
-
Zeger, S.L.1
Liang, K.Y.2
Albert, P.S.3
-
16
-
-
0027053029
-
An overview of methods for the analysis of longitudinal data
-
Zeger SL, Liang KY. An overview of methods for the analysis of longitudinal data. Stat Med. 1992 ; 11: 1825-1839
-
(1992)
Stat Med
, vol.11
, pp. 1825-1839
-
-
Zeger, S.L.1
Liang, K.Y.2
-
17
-
-
0029913882
-
Defining the clinical course of multiple sclerosis: Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis
-
Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996 ; 46: 907-911
-
(1996)
Neurology
, vol.46
, pp. 907-911
-
-
Lublin, F.D.1
Reingold, S.C.2
-
18
-
-
77957044257
-
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity
-
Jones JL, Anderson JM, Phuah CL, et al. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain. 2010 ; 133: 2232-2247
-
(2010)
Brain
, vol.133
, pp. 2232-2247
-
-
Jones, J.L.1
Anderson, J.M.2
Phuah, C.L.3
-
19
-
-
79953761792
-
A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis
-
Nikic I, Merkler D, Sorbara C, et al. A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med. 2011 ; 17: 495-499
-
(2011)
Nat Med
, vol.17
, pp. 495-499
-
-
Nikic, I.1
Merkler, D.2
Sorbara, C.3
-
20
-
-
79959744924
-
Enhancing remyelination in disease-can we wrap it up?
-
Kotter MR, Stadelmann C, Hartung HP. Enhancing remyelination in disease-can we wrap it up?. Brain. 2011 ; 134: 1882-1900
-
(2011)
Brain
, vol.134
, pp. 1882-1900
-
-
Kotter, M.R.1
Stadelmann, C.2
Hartung, H.P.3
-
21
-
-
0024586487
-
Serial magnetic resonance scanning in multiple sclerosis: A second prospective study in relapsing patients
-
Willoughby EW, Grochowski E, Li DK, et al. Serial magnetic resonance scanning in multiple sclerosis: A second prospective study in relapsing patients. Ann Neurol. 1989 ; 25: 43-49
-
(1989)
Ann Neurol
, vol.25
, pp. 43-49
-
-
Willoughby, E.W.1
Grochowski, E.2
Li, D.K.3
-
22
-
-
0025314243
-
Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group
-
Noseworthy JH, Vandervoort MK, Wong CJ, et al. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group. Neurology. 1990 ; 40: 971-975
-
(1990)
Neurology
, vol.40
, pp. 971-975
-
-
Noseworthy, J.H.1
Vandervoort, M.K.2
Wong, C.J.3
-
23
-
-
0026844653
-
Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Multiple Sclerosis Collaborative Research Group
-
Goodkin DE, Cookfair D, Wende K, et al. Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Multiple Sclerosis Collaborative Research Group. Neurology. 1992 ; 42: 859-863
-
(1992)
Neurology
, vol.42
, pp. 859-863
-
-
De, G.1
Cookfair, D.2
Wende, K.3
-
24
-
-
0029131208
-
Measuring patient-centered outcomes in neurologic disease. Extending the Q-TWiST method
-
Schwartz CE, Cole BF, Gelber RD. Measuring patient-centered outcomes in neurologic disease. Extending the Q-TWiST method. Arch Neurol. 1995 ; 52: 754-762
-
(1995)
Arch Neurol
, vol.52
, pp. 754-762
-
-
Schwartz, C.E.1
Cole, B.F.2
Gelber, R.D.3
-
25
-
-
0028928973
-
The natural history of multiple sclerosis
-
Weinshenker BG. The natural history of multiple sclerosis. Neurol Clin. 1995 ; 13: 119-146
-
(1995)
Neurol Clin
, vol.13
, pp. 119-146
-
-
Weinshenker, B.G.1
-
26
-
-
0025978558
-
An assessment of disability rating scales used in multiple sclerosis
-
Francis DA, Bain P, Swan AV, et al. An assessment of disability rating scales used in multiple sclerosis. Arch Neurol. 1991 ; 48: 299-301
-
(1991)
Arch Neurol
, vol.48
, pp. 299-301
-
-
Francis, D.A.1
Bain, P.2
Swan, A.V.3
-
27
-
-
0026024427
-
Observer disagreement in rating neurologic impairment in multiple sclerosis: Facts and consequences
-
Verdier-Taillefer MH, Zuber M, Lyon-Caen O, et al. Observer disagreement in rating neurologic impairment in multiple sclerosis: Facts and consequences. Eur Neurol. 1991 ; 31: 117-119
-
(1991)
Eur Neurol
, vol.31
, pp. 117-119
-
-
Verdier-Taillefer, M.H.1
Zuber, M.2
Lyon-Caen, O.3
-
28
-
-
0030911461
-
Primary progressive multiple sclerosis
-
Thompson AJ, Polman CH, Miller DH, et al. Primary progressive multiple sclerosis. Brain. 1997 ; 120: 1085-1096
-
(1997)
Brain
, vol.120
, pp. 1085-1096
-
-
Thompson, A.J.1
Polman, C.H.2
Miller, D.H.3
-
29
-
-
0032946328
-
The natural history of multiple sclerosis: A geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis
-
Cottrell DA, Kremenchutzky M, Rice GP, et al. The natural history of multiple sclerosis: A geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain. 1999 ; 122: 625-639
-
(1999)
Brain
, vol.122
, pp. 625-639
-
-
Cottrell, D.A.1
Kremenchutzky, M.2
Rice, G.P.3
-
30
-
-
3042601982
-
The PROMiSe trial: Baseline data review and progress report
-
Wolinsky JS. The PROMiSe trial: Baseline data review and progress report. Mult Scler. 2004 ; 10 (Suppl. 1). S65 - S71
-
(2004)
Mult Scler
, vol.10
, Issue.SUPPL. 1
-
-
Wolinsky, J.S.1
-
31
-
-
70149121896
-
Oral versus intravenous steroids for treatment of relapses in multiple sclerosis
-
Burton JM, O'Connor PW, Hohol M, et al. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev. 2009 ;: CD006921
-
(2009)
Cochrane Database Syst Rev
, pp. 006921
-
-
Burton, J.M.1
O'Connor, P.W.2
Hohol, M.3
-
32
-
-
0028279178
-
Establishment and use of multiple sclerosis registers-EDMUS
-
Confavreux C. Establishment and use of multiple sclerosis registers-EDMUS. Ann Neurol. 1994 ; 36: S136 - S139
-
(1994)
Ann Neurol
, vol.36
-
-
Confavreux, C.1
|